Efficacy of Protamine Zinc Recombinant Insulin for Treating Diabetes Mellitus in Cats
ACVIM 2008
R.W. Nelson1; K. Henley2; C. Cole2
1School of Veterinary Medicine, University of California, Davis, CA, USA; 2IDEXX Pharmaceuticals, Inc, Greensboro, NC, USA

The objective of this study was to evaluate the effects of a protamine zinc recombinant insulin (PZIR) on control of glycemia in cats with diabetes mellitus. 126 cats with newly diagnosed diabetes and 13 cats with poorly controlled diabetes were treated with PZIR twice daily for 45 days. Control of glycemia was assessed on days 7, 14, 30, and 45 by evaluation of clinical response, body weight, serum fructosamine, and blood glucose concentrations determined 1, 3, 5, 7, and 9 hours after administration of PZIR. Adjustments in dosage of PZIR were made as needed to attain control of glycemia.

PZIR administration resulted in a significant (p<0.001) decrease in 9 hr mean blood glucose, mean blood glucose nadir, and serum fructosamine concentrations and a significant (p<0.05) increase in mean body weight in the 139 diabetic cats at day 45, compared with day 0. 84% of the diabetic cats, including 9 poorly controlled, attained good diabetic control by day 45, based on improvement in clinical signs, physical examination, and blood parameters used to assess control of glycemia. Hypoglycemia was identified in 160 of 690 9-hr serial blood glucose curves involving 87 cats.

Results of this study demonstrate that PZIR is safe and effective for control of glycemia in cats with newly diagnosed and poorly controlled diabetes.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Richard Nelson

MAIN : SA Endocrinology : Protamine Zinc Recombinant Insulin
Powered By VIN